Table of contents for Overdose : how government regulation stifles pharmaceutical innovation / Richard A. Epstein.

Bibliographic record and links to related information available from the Library of Congress catalog.

Note: Contents data are machine generated based on pre-publication provided by the publisher. Contents may have variations from the printed book or be incomplete or contain other coding.


Counter
Contents
Preface 000
Part I Property and Progress
1. Rising Expectations¿and Diminishing Returns 000
2. Property Generally: Externalities, Coordination, and the Public Domain 000
3. Intellectual Property: The Public Domain and Private Rights 000
Part II Maintaining the Public/Private Interface
4. Taming Conflict of Interests 000
5. Federally Sponsored Research Under Bayh-Dole 000
Part III Intellectual Property and Its Regulation
6. The Anticommons 000
7. The Single Monopoly: Current Patent Limitations 000
8. Rate Regulation: An Unneeded Swamp 000
9. Patent Purchases: A Second Swamp 000
10. Socialization of R&D: The Final Swamp 000
Part IV The FDA: Purity, Safety, Effectiveness
11. The Steady Expansion of FDA Power 000
12. FDA Versus the Individual: Upstream or Downstream Decision Making 000
13. Drug Withdrawal: Too Much, Too Soon 000
Part V Pharmaceutical Marketing
14. Getting the Drugs to Market 000
15. Deceptive Marketing 000
Part VI Liability for Pharmaceuticals
16. Tort Preliminaries 000
17. Product Liability for Prescription Drugs: Manufacturing and Design Cases 000
18. The Main Event: Misrepresentation, Overpromotion, and Duty to Warn 000
Conclusion: Socialized Medicines 000
Notes 000
Index 000

Library of Congress Subject Headings for this publication:

Pharmaceutical industry -- Government policy -- United States.
United States. Food and Drug Administration.
United States. Food and Drug Administration.
Drug Industry -- United States.
Public Policy -- United States.
Government Regulation -- United States.